Cite
HARVARD Citation
Khushalani, N. et al. (n.d.). 797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel). Journal for immunotherapy of cancer. pp. A476-A477. [Online].